Administration of subcutaneous interferon beta 1a in the evening: data from RELIEF study.

Journal of Neurology
Francesco PattiRELIEF Study Group

Abstract

Subcutaneous recombinant interferon-beta 1a (IFN-β1a SC) is indicated for treatment of relapsing multiple sclerosis (RMS); however, it is associated with development of flu-like syndrome (FLS) in 75% of patients. No recommendations are available on whether evening or morning administration could induce better or worse FLS. Primary objective was to investigate whether morning administration of IFN-β1a 44 µg (Rebif) would affect the severity of FLS versus evening administration, in patients with RMS. Secondary objectives were to investigate whether timing of administration could lead to a better quality of life. Multicenter, open-label, 12-week, randomized, controlled, parallel-group, phase 4 study. Of 217 patients screened at 29 Italian sites, 200 were included in the study. Among these, 104 patients were randomized to IFN-β1a SC administration in the morning and 96 in the evening. Morning administration resulted in higher FLS scores, as measured by the Multiple Sclerosis Treatment Concern Questionnaire, at week 4 (p = 0.0083) and week 8 (p = 0.0079); however, the difference was no longer significant at the end of 12 weeks. IFN-β1a evening injections in the first 8 weeks of treatment led to an improvement in FLS; when continuing...Continue Reading

References

Jun 13, 2001·Neurology·UNKNOWN Secondary Progressive Efficacy Clinical Trial of Recombinant Interferon-Beta-1a in MS (SPECTRIMS) Study Group
Jun 27, 2001·Neurology·UNKNOWN PRISMS Study Group and the University of British Columbia MS/MRI Analysis Group.
May 17, 2005·Physical Medicine and Rehabilitation Clinics of North America·Dawn M Ehde, Charles H Bombardier
Aug 2, 2005·European Journal of Neurology : the Official Journal of the European Federation of Neurological Societies·R GoldUNKNOWN PRISMS Study Group
Jan 31, 2006·Acta Neurologica Scandinavica·J A CramerM Glassman
Aug 13, 2008·Current Medical Research and Opinion·Harold Moses, David W Brandes
Jun 16, 2009·Neurology·John F Foley, David W Brandes
Sep 22, 2010·Nature Reviews. Neurology·Rex D Simmons
Jan 29, 2011·Clinical Neurology and Neurosurgery·Yann NadjarAlain Créange
Jan 12, 2012·Journal of Rehabilitation Research and Development·Alex D Rae-GrantJodie K Haselkorn
May 6, 2014·Lancet Neurology·Peter A CalabresiUNKNOWN ADVANCE Study Investigators
Sep 10, 2015·Mini Reviews in Medicinal Chemistry·Valery A Trufakin, Anna V Shurlygina

❮ Previous
Next ❯

Citations

Oct 8, 2020·Clinical Pharmacology and Therapeutics·James C WaltonRandy J Nelson

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.